Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
LUNAC Therapeutics are a drug discovery spin-out from University of Leeds, developing next generation oral anti-coagulant therapies.
News
Lunac Therapeutics Gains Funding for Project to Develop Next-Generation Anticoagulant Pharmaceutical Technology
A drug discovery company based in the United Kingdom, Lunac Therapeutics, has been awarded funding worth £3.14 million (US$4.11 million) under Innovate UK's Biomedical Catalyst program.
Read more
Report
Lunac Therapeutics divulges new FXIIa inhibitors
Lunac Therapeutics Ltd. has synthesized coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of arthritis, Alzheimer
Read more
Report
LUNAC Therapeutics wins 'Start Up of the Year' at National Medilink Healthcare Business Awards
LUNAC has been announced as the Start Up of the Year winner at the 2021 Medilink North of England National Healthcare Business Awards.
Read more
Report
LUNAC Therapeutics Appoints Julian Howell as Chief Executive Officer
LUNAC Therapeutics is pleased to announce the appointment of Julian Howell as Chief Executive Officer.
Read more
Report
LUNAC Therapeutics wins 'Start Up of the Year' at Medilink Healthcare Business Awards
LUNAC has been announced as the winner of 'Start Up of the Year' at the 2021 Medilink North of England Healthcare Business Awards.
Read more
Report
Pro access
Upgrade to see all 16 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.